Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

ArmReported safety
Vorasidenib 40 mggrade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)grade 3 or 4 ALT increase (pooled): 9%, labelgrade 3 or 4 AST increase (pooled): 4.8%, labelpermanent discontinuation for ALT elevation: 2.9%, label
Vorasidenib Phase 1 dosesn/r
Safusidenib (AB-218, DS-1001) 250 mgn/r
Olutasidenib 150 mggrade 3 to 4 ALT increase: 12%grade 3 to 4 AST increase: 12%
Ivosidenib Phase 1 dosesn/r
IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in sourcen/r
Olaparib 300 mgn/r

A count stays a count. This page does not turn a count into a percent.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.